And sorry for the few-minute delay. I'm Tim Anderson, a large-cap and U.S. pharma analyst and biotech analyst at Bank of America. We're excited to have Johnson & Johnson with us today ...

Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America. Happy to have Lilly here on this final day of the conference. We have Lucas Montarce, who's ...

Thanks for joining us. I’m Tim Anderson, the U.S. large cap pharma and biotech analyst of Bank of America and excited to have Gilead with us today, specifically Johanna Mercier, who serves as ...

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

in our opinion," BofA Securities analyst Tim Anderson wrote in a note to clients Thursday. The overarching concern with the CVS/Novo Nordisk deal is whether this starts a race to the bottom on ...

Recently, BofA’s four-star-rated analyst Tim Anderson reiterated a Buy rating on LLY stock, forecasting a growth rate of over 20%. Anderson’s Buy rating reflects the company’s strong growth ...

BofA Securities analyst Tim Anderson told Yahoo Finance that the market had overreacted to the news. "I think its going to become more and more known that this is a lot of hype. And what Novo has ...

Bank of America Securities analyst Tim Anderson said that it's been more than a decade since healthcare was really considered safe, but it is still a defensive play.

A rich history of a bygone era in Anderson County is on display in the town of Rocky Top, originally known as Coal Creek. A unique museum shows what life was like when ...